JAJesselyn Angellee

Jesselyn Angellee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jesselyn Angellee has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Anabolic Androgenic Steroid Withdrawal Syndrome: A Review for Healthcare Practitioners

    by William, Jesselyn Angellee

    The non-medical use of anabolic androgenic steroid (AAS) has significantly increased among athletes, bodybuilders, and individuals who focus on physical performance as well as body aesthetics. Although AAS has certain therapeutic benefits, use outside of medical supervision can lead to AAS withdrawal syndrome. This condition is characterized by physical and psychological symptoms, such as fatigue, decreased libido, anxiety, depression, and sleep disturbances. Its primary mechanism is the suppression of the hypothalamic–pituitary–gonadal (HPG) axis, which reduces endogenous testosterone production after discontinuation of AAS. Disruption of this axis not only decreases endogenous testosterone production but also alters gonadotropin hormone dynamics and androgen receptor responsiveness. Several risk factors, such as high doses, prolonged duration of use, specific usage patterns (cycling, stacking, pyramiding), and a history of psychological disorders, may exacerbate withdrawal symptoms. Management of AAS withdrawal syndrome includes short-term hormonal therapy, agents that stimulate endogenous testosterone production, psychological interventions, and physical rehabilitation. A multidisciplinary approach and close medical monitoring are required to restore endocrine function, prevent complications, and improve the patient’s psychological well-being. This paper provides a comprehensive overview to assist healthcare practitioners in recognizing, diagnosing, and appropriately managing AAS withdrawal syndrome.

  • Open Access

    Exploring the Interplay of Mental and Metabolic Factors in Erectile Dysfunction Management: A Case Report

    by Jesselyn Angellee, Sally Suharyani, Tjahjo Djojo Tanojo, Cennikon Pakpahan, William William, Natasha Susanto Utomo

    Background: Erectile dysfunction (ED) affects 20-50% of men globally and considerably diminishes the patients’ and their partners’ quality of life. This condition has multifactorial causes, including depression and metabolic syndrome, resulting in a complicated interaction of physical and psychological components. Case: A man in his mid-twenties presented to the Andrology outpatient clinic at Dr. Soetomo General Hospital with a sudden onset of ED, reporting a decrease in his Erection Hardness Score (EHS) from 3-4 to 1 following penetration attempts. He had a history of childhood attention deficit hyperactivity disorder (ADHD) and recent unemployment, resulting in profound depression. Prior inconsistent treatments encompassed sertraline, fluvoxamine, and clobazam. Physical and laboratory examinations revealed metabolic syndrome. The patient was diagnosed with severe ED secondary to mixed etiology, class II obesity, major depressive episode, and metabolic syndrome. He received education on the diagnosis, possible underlying causes, and management options. Discussion: The case presented illustrates the intricate interplay between ED and comorbidities such as depression and metabolic syndrome. Depression exacerbates ED through hormonal dysregulation and reduced parasympathetic activity, while metabolic syndrome contributes to ED through endothelial dysfunction and nitric oxide (NO) depletion. Effective ED management requires a multidisciplinary approach, combining lifestyle modifications, psychological support, and pharmacological treatment. Tailored strategies addressing both physical and psychological aspects are essential for improving outcomes. Conclusion: Comprehensive and integrative care in managing ED, particularly when associated with complex comorbidities, is needed to enhance the patient’s erectile function and quality of life.

  • Tribulus terrestris for management of patients with erectile dysfunction: a systematic review and meta-analysis of randomized trials

    by Sally Suharyani, Bella Amanda, Jesselyn Angellee, William William, Timotius Ivan Hariyanto, Reny I’tIshom

    Tribulus terrestris is a medicinal herb purported to enhance reproductive function, particularly in instances of erectile dysfunction (ED). This study aims to assess the effectiveness and safety of administering Tribulus terrestris to patients with ED. We performed a systematic literature review in the Cochrane Library, Medline, Scopus, and Europe PMC databases utilizing particular keywords. The primary endpoint in this study is International Index of Erectile Function, that may be in abridged form (IIEF-5) or full form (IIEF-15). The outcomes of continuous variables were aggregated into the mean difference (MD) with corresponding 95% confidence intervals (95% CI) utilizing random-effects models. Eight studies were selected for inclusion. After the intervention with Tribulus terrestris, the IIEF-5 [MD 4.21, p < 0.00001] and IIEF-15 scores [MD 15.88, p = 0.0004] were markedly elevated compared to their pre-supplementation levels, as per our comprehensive analysis. Additionally, on both the IIEF-5 [MD 3.23 (95%CI 1.89, 4.58), p < 0.00001] and IIEF-15 [MD 14.44 (95%CI 5.75, 23.14), p = 0.001], Tribulus terrestris outperformed placebo. However, the two groups were not significantly different in terms of total testosterone levels. We observed no difference in the incidence of adverse events between Tribulus terrestris and placebo. Tribulus terrestris supplementation may offer benefits in improving erectile function among patients with ED with a relatively good safety profile.


  • Open Access

    L-glutamine Supplementation Enhances Sperm Motility and Viability in Low-count Samples during Cryopreservation: Evidence from a Nonrandomized In vitro Study

    by Jesselyn Angellee, Christian Christopher Sunnu, Sally Suharyani, Ninik Darsini, Agustinus Agustinus, Reny I’tIshom, William William, Pratik Patel, Daniel Patterson

    Introduction: Sperm cryopreservation is a cornerstone of assisted reproductive technologies, yet the process often induces reactive oxygen species (ROS) formation, which compromises plasma membrane integrity and subsequently reduces motility and viability. L-glutamine has emerged as a promising in vitro supplement to mitigate these deleterious effects, particularly of oligozoospermic samples. This study aimed to assess the effectiveness of in vitro L-glutamine supplementation in maintaining the motility and viability of low-count sperm during cryopreservation. Methods: Eight samples were collected from volunteers attending the Medical Biology Laboratory, Faculty of Medicine, Universitas Airlangga, in September and October 2023. Each sample was divided into two cohorts: the treatment group, which received 10 mM L-glutamine supplementation, and the control group, which received no supplementation. Individual sperm (10–15 per sample) were isolated using a micromanipulator and transferred onto cryo straws containing sperm freezing media before undergoing freezing and subsequent thawing. The postthaw sperm motility and viability were compared between groups using paired t-test, with a statistical significance level set at 5%. Results: The L-glutamine supplementation group indicated markedly enhanced sperm motility relative to the control group (9.54 ± 4.55% versus 1.75 ± 4.95%, respectively; P < 0.05). While sperm viability was also higher in the L-glutamine group, the difference lacked statistical significance (65.25 ± 8.48% versus 52.63 ± 10.47%, respectively; P > 0.05). Conclusion: In vitro L-glutamine supplementation during cryopreservation substantially preserves greater motility of low-count sperm and offers a modest improvement in viability. This approach holds promise for optimizing outcomes in sperm cryopreservation protocols.


  • Open Access

    Non-obstructive Azoospermia in Male with Y-Chromosome Microdeletion: A Case Report

    by Jesselyn Angellee, Agustinus Agustinus, Pety Narulita, Markus Christian Hartanto, William William, Sally Suharyani

    Male factors have contributed to at least 50% of all infertility cases worldwide. Numerous factors causing male infertility have been identified, one of which is azoospermia due to genetic defects. The detection of Y-chromosome microdeletion may assist in diagnosing male infertility as well as predicting the success rate of testicular sperm extraction. A man in his mid-thirties visited the Andrology outpatient clinic at Dr. Soetomo General Hospital accompanied by his wife. They have been married for eight years and have had regular unprotected sexual intercourse, but pregnancy has never been achieved. The patient’s semen analyses showed azoospermia in three examinations conducted at different times. Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were significantly increased, and genetic screening showed microdeletion in the Azoospermia Factor b (AZFb) subregion. Y-chromosome microdeletion is the second most common genetic defect causing azoospermia after Klinefelter syndrome. The AZF region in the distal part of the Y chromosome plays a key role in regulating spermatogenesis. Mutation or loss of any subregions in this factor may affect spermatogenesis, with the worst outcome being azoospermia. Detailed examinations are important to determine the cause of azoospermia, which may assist a physician in choosing the appropriate management for this condition. Infertile men with Y-chromosome microdeletion face challenges in reproducing naturally. They may also need genetic counseling regarding the possibility of passing on this genetic defect to their offspring and information on how to prevent it.

  • Open Access

    Sperm Quality and Deoxyribonucleic Acid Fragmentation after 5 and 10 min Centrifugation with Swim-Up Processing Technique: A Prospective Cohort Study

    by Binarwan Halim, Jesselyn Angellee, Hilma Putri Lubis, Bob Bachsinar

    AIM: This study aimed to assess the difference in sperm concentration, total motility, progressive motility, and deoxyribonucleic acid (DNA) fragmentation index (DFI) before and after processing with 5 and 10 min swim-up (SU). METHODS: Fifty patients who met the study inclusion criteria from June 2020 to October 2020 were subjected to routine semen and sperm DNA fragmentation analysis. Each of the samples was then divided into three tubes, one as control and the others were processed using the SU method with 5 and 10 min centrifugation time, respectively. After being processed, the samples were subjected again to routine semen and sperm DNA fragmentation analysis. The results were being compared among three groups. RESULTS: The sperm concentration after 5 and 10 min SU (27.78–39.79 and 35.36–51.09, respectively; p < 0.05) was significantly higher compared to fresh semen (24.85–32.33). The total motility before and after 5 and 10 min SU were 43.78–51.08, 97.66–98.20, and 97.86–98.20, respectively. The progressive motility after 5 and 10 min SU (0–41 and 0–54, respectively) was significantly higher than fresh semen (0–24; p < 0.05). The DFI was significantly better after 5 min SU (3.82–6.98) compared to fresh semen and after 10 min SU (13.48–19.04 and 1–25, respectively; p < 0.05). CONCLUSION: Prolonged centrifugation time may yield a higher number of sperm concentration and motility, but it may also lead to a higher DFI. Hence, a shorter centrifugation time should be used for a better semen quality intended for assisted reproductive technologies.